Tenon Medical, Inc. is a healthcare company focused on developing innovative solutions for the treatment of sacroiliac joint disorders. By leveraging advanced medical technology, the company aims to improve surgical outcomes and enhance patient recovery through its minimally invasive procedures and products. Tenon Medical is committed to addressing the unmet needs of patients suffering from chronic pain related to sacroiliac joint dysfunction by providing effective, safe, and durable treatment options, thus contributing to the ongoing advancement of orthopedic and pain management practices. Read More
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regular session. The market value of their outstanding shares ...
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-market session. The company's market cap stands at $4.0 million. ...
LOS GATOS, CA / ACCESS Newswire / May 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the first quarter ended March 31, 2026 after market close on Tuesday, May 12, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.
LOS GATOS, CA / ACCESS Newswire / March 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the closing of a private placement of senior convertible promissory notes with several institutional and high net worth investors for aggregate gross proceeds of $4.3 million before deducting fees of the placement agent.
LOS GATOS, CA / ACCESS Newswire / November 14, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the successful closing of its previously announced at-the-market private investment in public equity (the "PIPE") financing.
~ Record revenue of $1.2 million, a 32% year-over-year increase, reflecting record volume in Catamaran® SI Joint Fusion System procedures and the addition of SImmetry® SI Joint Fusion Product Sales ~
